試す 金 - 無料
Lactose India unveils new specialized grades
Chronicle Pharmabiz
|November 27, 2025
IN a significant boost to India’s pharmaceutical sector, Lactose India Ltd (LIL) has launched a new lineup of specialized lactose grades, marking a pivotal advancement in the country’s domestic production capabilities.
Established in 1991 and headquartered along the Vadodara-Ahmedabad Expressway in Poicha, LIL is leveraging its expansive state-of-the-art five-acre facility to deliver high-value high performance lactose products. This move not only expands their product portfolio but also aligns seamlessly with the national vision of “Atma Nirbhar Bharat” (Self-Reliant India) and “Make in India,” reducing the nation’s dependence on imports for critical pharmaceutical excipients.
In keeping with its commitment to responsible growth, Lactose India’s focus on sustainability drives operational excellence — through optimized energy-efficient processes, reduced emissions, conscious material sourcing, wastewater recycling systems to promote greener practices across its product lifecycle. Every batch reflects LIL’s holistic belief that progress and environmental governance must go hand in hand.
Lactose India, a recognized leader in lactose monohydrate production with an installed capacity of 12,000 metric tons per annum - is set to double following a recent acquisition - is a market leader for its regular grades such as 200 Mesh, 125M, 450M, PHA, DC2050, DC60, 80M, 100M, 325M, and IMP variants in milled and sieved forms. These have served both domestic and overseas markets effectively.
The introduction of specialized segments marks a strategic evolution, targeting niche applications in pharmaceuticals, including excipients, APIs, and formulations - all housed within a single campus featuring dedicated production blocks, warehouses, and quality assurance offices, ensuring world class standards in every batch.
New specialized grades: Innovation meets demand
このストーリーは、Chronicle Pharmabiz の November 27, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Chronicle Pharmabiz からのその他のストーリー
Chronicle Pharmabiz
Home-grown CAR-T cell therapies gaining ground
INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.
4 mins
November 27, 2025
Chronicle Pharmabiz
NPPA extends price fixation on orthopaedic implants for 1 year
IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.
1 mins
November 27, 2025
Chronicle Pharmabiz
FICCI envisages it's Smart AAMs to boost healthcare
In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.
1 min
November 27, 2025
Chronicle Pharmabiz
DoP asked to bring policy for affordable drug pricing
THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.
1 mins
November 27, 2025
Chronicle Pharmabiz
Ramaiah emphasises need for bone health and osteoporosis diagnosis
RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.
2 mins
November 27, 2025
Chronicle Pharmabiz
Nathealth calls for action in 2026-27 Union Budget
NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.
1 mins
November 27, 2025
Chronicle Pharmabiz
Hotspots & growth opportunities in biomanufacturing
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
3 mins
November 27, 2025
Chronicle Pharmabiz
Omega Hospitals acquires Cytecare Hospitals
Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.
2 mins
November 27, 2025
Chronicle Pharmabiz
Devices sector hails withdrawal of QCOs
THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.
1 min
November 27, 2025
Chronicle Pharmabiz
'There is urgent need for tech-focused regulatory approach for med devices'
THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.
2 mins
November 27, 2025
Listen
Translate
Change font size
